Table 1.

Active Clinical Trials for NF1-OPG

Agent	Study Number	Status	Sponsor	Phase	Ages	Primary Outcome
Selumetinib	NCT03326388	Recruiting	Great Ormond Street Hospital	I/II	3 to 18 years	Maximum Tolerated Dose
Selumetinib	NCT01089101	Active, not recruiting	NCI	I/II	3 to 21 years	Maximum tolerated dose and response rate
Selumetinib	NCT03871257	Recruiting	NCI	III	2 to 21 years	Event-free survival and visual acuity improvement
Vinblastine ± bevacizumab	NCT02840409	Recruiting	The Hospital for Sick Children	II	6 months to 18 years	Response rate
Lenalidomide	NCT01553149	Active, not recruiting	NCI	II	Up to 21 years	Response rate
Poly-ICLC	NCT04544007	Recruiting	University of Alabama at Birmingham, NFCTC	II	Up to 22 years	Response rate

Abbreviations: Poly-ICLC, Polyinosinic-Polycytidylic; NCI, National Cancer Institute; NFCTC, Neurofibromatosis Clinical Trials Consortium.